argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
791.45
-8.55 (-1.07%)
Oct 6, 2025, 1:20 PM EDT - Market open
argenx SE Employees
argenx SE had 1,599 employees as of December 31, 2024. The number of employees increased by 451 or 39.29% compared to the previous year.
Employees
1,599
Change (1Y)
451
Growth (1Y)
39.29%
Revenue / Employee
$1,951,733
Profits / Employee
$800,749
Market Cap
48.72B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,599 | 451 | 39.29% |
Dec 31, 2023 | 1,148 | 305 | 36.18% |
Dec 31, 2022 | 843 | 193 | 29.69% |
Dec 31, 2021 | 650 | 314 | 93.45% |
Dec 31, 2020 | 336 | 148 | 78.72% |
Dec 31, 2019 | 188 | 83 | 79.05% |
Dec 31, 2018 | 105 | 32 | 43.84% |
Dec 31, 2017 | 73 | 15 | 25.86% |
Dec 31, 2016 | 58 | 17 | 41.46% |
Dec 31, 2015 | 41 | 9 | 28.13% |
Dec 31, 2014 | 32 | 10 | 45.45% |
Dec 31, 2013 | 22 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ARGX News
- 2 days ago - argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 - GlobeNewsWire
- 18 days ago - FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations - Business Wire
- 19 days ago - argenx SE - Special Call - Seeking Alpha
- 24 days ago - argenx: Bullish On This R&D Focused Biotech Stock - Seeking Alpha
- 4 weeks ago - Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win - Benzinga
- 6 weeks ago - argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - GlobeNewsWire